<DOC>
	<DOC>NCT00866138</DOC>
	<brief_summary>This phase 2 study was designed to assess the safety and efficacy of masitinib (AB1010) in patients with relapsing/refractory t(4;14) Multiple Myeloma. Response and progression were assessed according to the Blad√© revised IMWG criteria1 from lowest point.</brief_summary>
	<brief_title>A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<criteria>Confirmed multiple myeloma with a t (4; 14) translocation by FISH and PCR, expressing or not expressing FGFR3 identified by FACS Patients with Multiple Myeloma progressing or relapsing after at least two prior therapies (including conventional chemotherapy and/or high dose therapy) or who get a reduction of Mprotein less than 75% within 3 months after a high dose treatment (Melphalan 200mg/m2) or after the plateau obtained for 3 months duration following to a conventional chemotherapy Life expectancy &gt; 3 months Patient with rapidly progressive disease with cytopenia and / or renal failure have to be stabilized with chemotherapy (if possible 3 cycles of VTD ( Bortezomib/Thalidomide/dexamethasone) or high dose Melphalan regimen followed by a 4 weeks washout period before the inclusion in the study. Patients must have a clearly detectable and quantifiable monoclonal M component value (&gt;5 g/l) in the serum and / or urine light chain excretion (&gt;0,5 g/d) ECOG = 0 2 Prior corticosteroids within two weeks before enrolment Prior local irradiation within two weeks before enrolment Prior experimental or standard treatment (other than steroids and local irradiation) within 30 days before enrolment Contraindication to high dose steroids (including ongoing active infection) Patient treated for a cancer other than MM within 5 years before enrolment, with the exception of basal cell carcinoma or cervical cancer in situ</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>t(4/14)</keyword>
	<keyword>relapsing</keyword>
	<keyword>refractory</keyword>
</DOC>